header logo image


Page 229«..1020..228229230231..240250..»

Pfizer vaccine found to give strong immune response to new Covid variants – The Guardian

February 14th, 2021 7:25 pm

People who have received two doses of the Pfizer vaccine have been found to have strong T-cell responses against the Kent and South African variants of Covid, suggesting that the vaccine will continue to protect against serious disease in the coming months.

In the first study to test immune responses against the variants circulating in populations, researchers found that although antibody responses against the new variants were blunted, they may still be high enough to protect most people from becoming infected, after a second dose of vaccine has been given.

Although previous studies had suggested that antibodies from those vaccinated with the Pfizer/BioNTech jab could recognise and neutralise viruses carrying some of the individual mutations found in the South African and Kent variants albeit at slightly lower levels compared with previous variants these were tested on engineered viruses rather than ones isolated from real patients.

These studies also did not look at T cells, which annihilate virus-infected cells and support the production of antibodies. Both immune responses help provide lasting protection after vaccination, but antibody responses are easier to measure.

William James, a professor of virology at the University of Oxford, and his colleagues took blood samples from people who had recovered from Covid-19, and health workers who had received either one or two doses of the Pfizer/BioNTech vaccine. They also obtained isolates of the B117 and B1.351 virus variants first identified in Kent and South Africa, and of an older variant similar to those circulating a year ago. Antibodies and T cells from the individuals were then tested against these viruses to see how well they performed.

The study, which has not yet been reviewed by other scientists, found that peoples antibodies were moderately effective against the original virus after their first dose of vaccine, less effective against the Kent variant, and were unable to neutralise the South African variant.

However, they had strong T-cell responses against all known variants after the first jab. It may not necessarily protect you against infection, but its very likely that this first dose will make it much easier for your immune system to make a good response the next time around, said James. We think this is why that second dose produces such a good strong antibody response, because the T cells are already there, ready to react.

The discovery that people who have recovered from Covid-19 and those who have received at least one dose of vaccine possess T cells capable of responding to the new variants is encouraging, because it suggests the T cells are recognising different regions of the spike protein to the antibodies. It could imply they will be more resilient to future variants. It doesnt promise you wont get ill from the new variants, but it does suggest theres something to work from and that your immune system can respond to them, said James.

Peoples antibody responses were also boosted by the second Pfizer jab. In more than 90% of cases, the antibodies that people are generating after the second dose are up at the sort of level that neutralises the virus and which we would expect to protect them from infection, said James. Were pretty confident that theyll be protected from infection by the South African strain and the Kent strain, as well as the [original] strain of the virus.

This virus hasnt finished evolving, but I think that as long as the vaccines get rolled out, and people get those second doses, were going to be in a much better position by the summer than we are now, said James.

Deborah Dunn-Walters, a professor of immunology at the University of Surrey, said: It does look like good news and suggests it is really important that people go back for their second dose of vaccine.

Prof Paul Morgan, the director of the Systems Immunity Research Institute at Cardiff University, said: I was supportive of the pragmatic decision to delay second doses to get more people immunised as quickly as possible and I still am. However, this work shows that the broad immune response needed to deal with current and future variants of concern is really dependent on boosting.

I think that the message is to get the second doses going as soon as possible perhaps as soon as the high-risk groups have all had first doses, which means pretty soon.

The findings also shed light on the risk of reinfection with new variants for people who have already recovered from Covid-19. T-cell activity was detected in all of them, but there was widespread variation in their antibody responses. In the best responders, you could still measure some neutralisation against even the South African strain, but those who had rather weaker responses had no neutralisation activity, said James. It shows its really important to get vaccinated, even if youve think youve recovered from the virus.

Although they did not look at immune responses from people injected with other types of Covid-19 vaccines, James suspects they will generate similar immune responses.

Morgan said: The findings add to the growing confidence that the current vaccines will have a large impact on the course of the pandemic, whether by completely protecting from or markedly ameliorating disease.

Follow this link:
Pfizer vaccine found to give strong immune response to new Covid variants - The Guardian

Read More...

Verily and Janssen to collaborate on home-based COVID-19 immune response study – PMLiVE

February 14th, 2021 7:25 pm

Life sciences research organisation Verily has partnered with Janssen Research & Development on a home-based study to investigate the early immune system response to COVID-19 infection.

The COVID-19 Immune Response Study will collect detailed information about how the SARS-CoV-2 virus affects the immune system, as soon as someone tests positive for COVID-19.

It will enrol participants with a confirmed, positive COVID-19 diagnosis, and the volunteers will participate from home.

Researchers will collect biological measurements, clinical and epidemiological data at the time of COVID-19 testing.

This information will be use to characterise biomarkers associated with progression of disease resulting from COVID-19 infection, over 28 days.

Acute respiratory distress syndrome caused by SARS-COV-2 and other viral and bacterial pathogens carries with it a high mortality rate, and more than 2.2 million people will suffer each year as a result, said James Merson, global head of infectious diseases R&D, Janssen.

Since immune response patterns observed in COVID-19 patients are similar to those caused by other respiratory pathogens, it is our hope to apply the findings from this study beyond COVID-19 to other illnesses that carry a high patient burden, he added.

The researchers will also collect real-world data from participants from up to two years prior to enrolment in the study and up to two years following the last study assessment.

There is a critical need for studies to identify biomarkers and potential signals which will give clinicians the ability to make evidence-based treatment decisions, allocate resources and facilitate more meaningful conversations with patients and families about the anticipated disease trajectory, said Faith Holmes, primary investigator of the COVID-19 Immune Response Study.

This study will have the ability to contribute to a myriad of future studies to shed some light on these issues, she added.

Verily is also conducting another programme the Baseline COVID-19 testing programme to advance and expand testing and containment for COVID-19 in the US.

Visit link:
Verily and Janssen to collaborate on home-based COVID-19 immune response study - PMLiVE

Read More...

Some coronaviruses steal genes of their host to evade immune system response: Study – BusinessLine

February 14th, 2021 7:25 pm

Some coronaviruses take in some genetic material of their host in order to blend in and become less detectable to the immune system, according to a study.

The study, published in the journal Viruses, noted that coronaviruses encompass a sophisticated evolutionary mechanism.

19 genetic variants of Covid-19 that can dodge antibodies found in India: Study

Research in this field is fundamental to understand the functioning of illnesses that can spread from animals to humans so that we can efficiently manage ecosystems and provide a balance between the species inhabiting them, said Mauro Delogu, a researcher at the University of Bologna and one of the authors of this study.

Researchers made this discovery while they were examining coronaviruses found in specimens of European hedgehogs (Erinaceus europaeus). They named this strain EriCoV.

The authors of the study observed that the viruses belong to the same strain of Beta-CoV responsible for Covid-19 as well as MERS. However, there is no evidence that they can spread to humans.

Study sheds more light on role played by immune system's T cells against coronavirus

These hedgehog coronaviruses are able to steal a gene (CD200) that belongs to the host. When combined with its receptor, this gene prevents an excessive inflammatory response. By incorporating this gene, the virus can hinder the immune defence of the host, the researchers explained.

The authors of the study believe that with this evolutionary strategy, coronaviruses can influence the duration of the infection and therefore prolong the time necessary to eliminate the virus.

See the original post:
Some coronaviruses steal genes of their host to evade immune system response: Study - BusinessLine

Read More...

Rare blood auto immune disorder appearing in very small amount of COVID vaccine recipients – WWLTV.com

February 14th, 2021 7:25 pm

If we recognize it early, it's treatable. It shouldn't hold us from encouraging them to get the vaccine.

NEW ORLEANS The CDC, the FDA, and the makers of the Pfizer and Moderna COVID-19 vaccines, are looking into reports of a rare blood disorder in a small number of people who got the vaccine.

After more than 31 million people in the U.S. have gotten a COVID vaccine, three dozen cases of a rare blood auto immune disorder, causing one death, have been reported.

Immune thrombocytopenia, or ITP, causes a lack of platelets, the part of the blood necessary for clotting.

There are some cases that have predisposing or history of autoimmune disorder, but some cases are occurring in otherwise healthy individuals, explained Dr. Maissaa Janbain, a Tulane Hematologist and Oncologist who is the Associate Director of the Louisiana Center for Bleeding and Clotting Disorders.

Autoimmune means your own immune system attacks cells that are supposed to be in your body. Dr. Janbain says this condition was not seen in the clinical trials, is extremely rare, and it is still unknown if it's a coincidence or linked to the vaccine.

When asked if the new ITP cases are about equal or fewer than is seen in the normal population, she replied, I would say they are even less.

If you are prone to autoimmune conditions vaccines can uncover this. Flu vaccines, and MMR vaccines have exposed this in people in the past, but natural viruses can too.

So the risk of getting ITP after getting coronavirus in the community is higher than with a vaccine. In fact there have been cases reported after COVID-19.

If we recognize it early, it's treatable. It shouldn't hold us from encouraging them to get the vaccine.

Here are the early signs:

Report those immediately to your doctor for a blood count.

Now if you already have the rare condition of ITP, the American Society of Hematology recommends this:

They are still encouraging patients with stable, chronic ITP, or ITP that has been in remission, to get the vaccines, said Dr. Janbain.

For now, Dr. Janbain wants her blood disorder patients to get the COVID vaccine. She'll just monitor them more closely.

On a separate note, the doctor says people on blood thinners should get the vaccine since getting the COVID infection can cause blood clots.

Get breaking news from your neighborhood delivered directly to you by downloading the new FREE WWL-TV News app now in theIOS App StoreorGoogle Play.

Stay up-to-date with the latest news and weather in the New Orleans area on the all-new free WWL TV app. Our app features the latest breaking news that impacts you and your family, interactive weather and radar, and live video from our newscasts and local events. LOCAL & BREAKING NEWS * Receive r...

Read the rest here:
Rare blood auto immune disorder appearing in very small amount of COVID vaccine recipients - WWLTV.com

Read More...

10 crucial vitamins and minerals children need to keep their immune systems healthy – Bromsgrove Standard

February 14th, 2021 7:25 pm

The British Nutrition Foundation outlines key nutrients that can help both children and parents fight infections, and explains which foods theyre in.

Having a healthy immune system is vital for both children and adults and what we eat plays a major part in this.

Paediatric infectious diseases expert Professor Kirsty Le Doare from St Georges, University of London, explains that the nutrients we get from food and our good gut bacteria, which are affected by food, help modulate the immune system and keep its natural balance, helping to protect us from disease and infection.

A healthy diet helps keep our immune system healthy and can help prevent or reduce the risk of immune-mediated diseases, she says. Malnutrition affects how the immune system works, and a poor, unhealthy diet thats low in vitamins and minerals can have the same effect.

To make it clearer to parents which foods can help keep children and young peoples immune systems healthy, the British Nutrition Foundation (BNF) has put together a list of the essential nutrients for the job.

All of these nutrients are essential for other functions in the body, as well as supporting the immune system, says Sara Stanner, the BNFs science director.

But whats really key isnt the role of one or two specific nutrients but how a range of vitamins and minerals are needed to support all the different ways the immune system fights off infections. And the best way to get all of these nutrients is to have a varied and balanced diet.

Every child is different, but its likely that having consistently low intakes of these nutrients, below the recommended amount, will mean their immune system may not be working at full strength, they may be more vulnerable to infections, and other aspects of their health may also be affected.

As well as nutrients such as protein and omega-3 fats, a number of vitamins and minerals have key roles in supporting the immune system.

The BNF says they are:

Vitamin A

Found in: Eggs, cheese, whole milk, liver. The body can also make vitamin A from beta-carotene, found in dark green leafy vegetables, orange-coloured fruits and vegetables (e.g. carrots, melon).

Did you know? Carrots are rich in beta-carotene which can be converted to vitamin A in the body three tablespoons will provide children under 10 with all they need for the day, and a baked sweet potato can give teenagers and adults all the vitamin A (as carotene) needed daily.

Vitamin B6

Found in: Poultry, fish, fortified breakfast cereals, chickpeas, soya beans, some fruit and vegetables (e.g. bananas, avocados, green peppers), nuts and seeds.

Did you know? A banana provides around a third of the vitamin B6 needed for a 4 to 10-year-old. A snack of walnuts (20g, or six halves) provides around 10% of the daily vitamin B6 requirement for teenagers and adults.

Vitamin B12

Found in: Meat, fish, milk, cheese, eggs, fortified breakfast cereals, fortified milk alternatives.

Did you know? Two tablespoons of tuna in a sandwich can provide all the vitamin B12 a child needs for the day, and two poached eggs will provide all the daily vitamin B12 adults and teenagers need.

Vitamin C

Found in: Citrus fruits, berries, kiwi fruit, green vegetables (e.g. broccoli, cabbage), cauliflower, peppers, tomatoes.

Did you know? Broccoli is a good vitamin C provider five small steamed florets will provide under 11s with the vitamin C they need for the day. A stir-fry with portions of sugar snap peas and red peppers will give teens and adults their required daily vitamin C.

Copper

Found in: Wholegrain breakfast cereals, wholewheat pasta, couscous, quinoa, shellfish, pulses, dried fruit.

Did you know? Baked beans are an easy source of copper that children often enjoy, and for teens and adults pulses used in soups, stews, and curries are good copper sources.

Vitamin D

Found in: Oily fish, eggs, some fortified breakfast cereals, some fortified dairy and dairy alternative products (check labels).

Did you know? During the UK autumn and winter the sun isnt strong enough for the body to make vitamin D, so we should eat foods rich in the vitamin. Oily fish is a good source, so try a sardine Bolognese. Children between one and four years should be given a daily 10mcg vitamin D supplement all year, and older children should take a supplement in autumn and winter.

Vitamin D is particularly important to keep childrens growing bones healthy, and our main source is from sunlight on our skin, explains Stanner. As over the past year many of us have been indoors more than usual, its even more important that both children and adults take vitamin D supplements, as its difficult to get enough from diet.

Folate

Found in: Green vegetables (e.g. broccoli, cabbage, spinach), chickpeas, oranges, berries, cheese, wholemeal bread.

Did you know? Green veg are packed with folate, whether its peas, plenty of lettuce, rocket and spinach in salads, and pak choi in stir fries.

Iron

Found in: Red meat, pulses, nut butters and seed pastes like peanut butter and tahini, fortified breakfast cereals, wholemeal bread, dried fruit.

Did you know? Surveys suggest around half of teenage girls and a quarter of women may have low iron intakes, so we should all try and include a variety of food sources of iron in our diets, advises Stanner. Vitamin C can help the body absorb iron, so try a glass of orange juice with fortified breakfast cereal.

Selenium

Found in: Nuts and seeds (particularly Brazil nuts, cashews, and sunflower seeds. For children under five years, nuts and seeds should be offered ground or as a nut butter/seed paste to reduce the risk of choking), eggs, poultry, fish, shellfish.

Did you know? Fish is a great selenium provider teenagers and adults should be eating at least two portions of fish a week, one of which should be oily (e.g. salmon, sardines).

Zinc

Found in: Meat, poultry, cheese, nuts and seeds (offered ground or as a nut butter/seed paste to the under fives), some shellfish (like crab and mussels), wholegrain breakfast cereals, wholegrain and seeded breads.

Did you know? Lean beef mince is a good source of zinc, so favourites like chilli, meatballs and cottage pie will all boost zinc intake. Wholegrains are also a source of zinc so try wholegrain cereal or a cheese sandwich on wholegrain bread with plenty of salad.

Continued here:
10 crucial vitamins and minerals children need to keep their immune systems healthy - Bromsgrove Standard

Read More...

What we know about Covid reinfection, immunity and vaccines – The Guardian

February 14th, 2021 7:25 pm

How long does natural protection from a first infection last?

There is no clearcut answer to this, but several studies suggest protection generated by a previous infection lasts for at least a few months.

According to one preprint study from Public Health England (PHE) released in January, which looked at hospital staff, the median interval between the first infection and reinfection was more than 160 days about five months. Meanwhile, a study from Qatar suggests protection by natural immunity of about 95% efficacy lasts about seven months.

Again, that is unclear. Different people will react differently to reinfection, depending on how their immune responses reacted to the first infection, probably, says Julian Tang, a clinical virologist and honorary associate professor in the respiratory sciences department at the University of Leicester.

For some, a second infection is less severe than the first. According to a study from Qatar, less than 0.2% of people tested positive for Covid at least 45 days after their first positive test, with only about a fifth of these showing strong or good evidence for reinfection. Of these 54 people, just one was hospitalised, and even then only with a mild infection.

A second study from Qatar yet to be peer-reviewed supports this, with two-thirds of reinfections only picked up through random or routine testing. Again it suggest reinfection is rare, with just 129 people out of 43,044 followed showing evidence of reinfection over a median of 16.3 weeks.

The PHE study also suggested that reinfection tended to be less severe, with about a third of those who caught Covid for a second time showing symptoms, compared with 78% for first infection.

But there have been a number of cases around the world of reinfection leading to worse disease.

A recent study from researchers in Brazil, about to be published in the Journal of Infection, found that of 33 people thought to have caught Covid for a second time, 12% were hospitalised one of whom died - although none required such care for their first infection.

If you didnt have a good immune response, you could get infected again by exactly the same virus, says Deborah Dunn-Walters, a professor of immunology at the University of Surrey and the chair of the British Society for Immunologys Covid-19 and immunology taskforce.

If that immune response was good, the chances of being reinfected by the same variant will be lower, but reinfection might still occur by other variants.

However, the situation is not black and white as this depends on the mutations a new variant contains, and how they affect the ability of the virus to infect the cell and its interactions with the bodys antibodies and T-cell responses generated by the immune system as a result of the previous infection.

The possibility for a new variant to fuel reinfections has been highlighted by researchers in Brazil: despite about three-quarters of the population of Manaus thought from antibody tests to have been infected with Covid by October, there was a sharp uptick in hospital admissions for Covid in January this year. One explanation, they say, is the emergence of new variants of the coronavirus that may evade immunity gained from earlier infection.

Indeed, research published this week by researchers in Oxford, yet to be peer-reviewed, revealed that people who had recovered from Covid showed T-cell activity towards new variants, including the South African variant. But in general their antibodies were less able to neutralise the Kent and South African variant than the original coronavirus variant, suggesting a potentially lower level of defence.

It appears so, but there are several factors at play. Whether you catch it or not is a combination of whether you have got immunity and whether you have seen [the virus], says Dunn-Walters.

Some people may be at greater risk because of social factors such as occupation, which means they have greater chance of coming into contact with the virus again for example, healthcare workers would be expected to be at greater risk of both infection and reinfection because of this.

But there are also biological factors that might leave some people more at risk of catching Covid for a second time. Each human is unique, as are their immune responses, which govern both the risk of reinfection and the severity of these reinfections, so it is very difficult to generalise research findings and clinical trial results to individuals in any population, says Tang.

Vaccination plays a key role in protecting individuals from a first infection. But it is also important for those who have already had Covid. While natural immunity can be gained from a previous infection, jabs give much more certainty over the level of protection produced and boost protection gained from a previous infection.

Vaccines may also offer greater protection against different variants. According to the preprint by Oxford researchers, people who received two doses of the Pfizer/BioNTech jab had a strong T-cell and antibody response against the original coronavirus and the Kent and South African variants, suggesting the vaccine probably offered protection against infection for all of these variants. That contrasts with the findings for those who had only previously had a natural infection.

Natural infection doesnt guarantee you immunity as well as perhaps the vaccination might, says Dunn-Walters.

While studies have suggested that some other Covid vaccines may be less effective against the South African variant than against the original or Kent variants of the coronavirus, experts say these jabs still offer good levels of protection against serious disease. Whats more, vaccines are being tweaked to better target new variants, a move that will also bolster protection.

This article was amended on 13 February 2021. The original incorrectly stated that a study about to be published in the Journal of Infection found that of 33 people thought to have caught Covid for a second time, one died, and 12 were hospitalised. It was actually 12.1% (four people) of the 33 who needed treatment in hospital.

Continued here:
What we know about Covid reinfection, immunity and vaccines - The Guardian

Read More...

Stem Cell Banking Market Analysis Revealing Key Drivers & Growth Trends through 2029: CCBC, CBR, ViaCord, Esperite, Vcanbio, and others. KSU |…

February 14th, 2021 7:24 pm

Stem Cell Banking Market

Stem Cell Banking Market Projections (2020-2029): The Global market Stem Cell Banking theologizes is the most recent of the world business market curves. The report prospects the current and frequent collectors, technological innovations, product supplementation, and their representation of performance broadly across the foreign market.

Thisphenomenalstudy on world-widebusiness includes the results of vital primary and secondary resources. These research findings are accepted by the companys skilled analysts and experts, providing rich in-depth information to associated partners, appraisers as well as captains of the industry.

Get a Sample Copy of this Report @ https://www.regalintelligence.com/request-sample/151669

Prominent players in the industry covered in the report:

CCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife Group, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech Group, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell, Stemade Biotech

Market split by Type, can be divided into:Umbilical Cord Blood Stem CellEmbryonic Stem CellAdult Stem CellOther

Market split by Application, can be divided into:Diseases TherapyHealthcare

Market split by Sales Channel, can be divided into:Direct ChannelDistribution Channel

Market segment by Region/Country including:North America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Spain etc.)Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)South America Brazil, Argentina, Colombia and Chile etc.)Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

Ourstudypasses through ahaven ofprofound qualitative and quantitativeresearch by industryexperts andprofessionals.Within the reportcontributes a broadperceptionof thepast as well ascurrent marketvista,which implies future statistics and prospects in position with the technical developments over time. Furthermore, the report includes and provides analyses of demand and supply, microeconomic and macroeconomic elements, administrative components and growth indices through the Stem Cell Banking marketplace. The report outlines keytacticsutilized bykey market participants.

Reach us to quote the effective price of this report (UPTO 50% OFF) @ https://www.regalintelligence.com/check-discount/151669

This report provides an accurate understanding and discovery of key geographic areas underway with market Stem Cell Banking, including critical segments and additional segments.The report sets out aspects of territorial growth and the size and scope of the market. Additionally, the report also deals with trading information such as business range, cost and revenue margin as well as gross value. However, this understanding assists readers in the conduct of consumer experts as well as major tactic to reach market share.

Substantivebeneficiaries:

Additional Information:

This reportcontributes to the following:

Important questions answered within this report:

About Us:We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service,reach us here 24/7.

Mention your Queries here to Get a Call from Our Industry Expert @sales@regalintelligence.com

Contact Us:Regal Intelligence: http://www.regalintelligence.comPh no: +1 231 930 2779 (U.S.) | +44 141 628 8787 (UK)

Follow this link:
Stem Cell Banking Market Analysis Revealing Key Drivers & Growth Trends through 2029: CCBC, CBR, ViaCord, Esperite, Vcanbio, and others. KSU |...

Read More...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Size Is Expected To Generate Huge Profits and Competitive Outlook – The Courier

February 14th, 2021 7:24 pm

TheAutologous Stem Cell and Non-Stem Cell Based Therapies Marketresearch report thoroughly explains each and every aspect related to the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Insight:

Autologous stem cell and non-stem cell based therapies market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 121.68 billion by 2027 growing at a CAGR of 3.75 % in the above-mentioned forecast period. The introduction of novelautologousstem cell based therapies inregenerativemedicine will help in driving the growth of the autologous stem cell and non-stem cell based therapies market.

Get Free Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) at: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market#utm_source=KA

This Free report sample includes:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Prominent Key Players Covered in the report:

Antria Inc., BrainStorm Cell Limited, Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., thinkBiotech LLC, Caladrius, Opexa Therapeutics, Inc., Orgenesis Inc, Regeneus Ltd,

Key Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast

TheAutologous Stem Cell and Non-Stem Cell Based Therapies marketreport provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Major Regions as Follows:

Get Table Of Contents of This Premium Research For Free @ https://www.databridgemarketresearch.com/toc/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market#utm_source=KA

The report includes accurately drawn facts and figures, along with graphical representations of vital market data. The research report sheds light on the emerging market segments and significant factors influencing the growth of the industry to help investors capitalize on the existing growth opportunities.

How insights and forecast from the reports could benefit you:

Why choose us:

Table Of Contents: Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Part 07:Five Forces Analysis

Part 08:Market Segmentation

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Part 16:Appendix

Make an Inquiry of theAutologous Stem Cell and Non-Stem Cell Based Therapies Market Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market#utm_source=KA

To summarize:

The global Autologous Stem Cell and Non-Stem Cell Based Therapies market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

We are grateful to you for reading our report. If you wish to find more details of the report or want customization, contact us. You can get a detail of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

More here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Size Is Expected To Generate Huge Profits and Competitive Outlook - The Courier

Read More...

Genentech Could Regain the Blindness-Related Disease Market with New Treatment – BioSpace

February 14th, 2021 7:23 pm

After announcing topline data from two identical Phase III trials, Roches Genentechhas doubled down on dataand is now showing positive results from four studiesfor itsnewestblindness-fighting treatment.

Faricimabis an injectable treatment to maintain the vision of patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). These are two of the leading causes of blindness withnAMDresponsible for 90% of all blindness resulting from AMD.

Genetechs Lucentis was thefirst FDA-approved drugprovento restore sight innAMDpatients.Since 2006 it had been a game-changer in theophthalmologyworld. But thenRegenerons Eyleacame in as the main contender andthe companies have had to share the market since 2011.

Genentech is now stepping it upwithfaricimab,a new class of medicine. Instead of focusing onthesingle protein targetVEGF, like Lucentis and Eylea,faricimabis a bispecific antibody.The drug targets two distinct pathways -via angiopoietin-2 (Ang-2) and VEGF-A.This approach bothreduces the growth of blood vessels on the retinalike its predecessorsandstabilizesvessels to reduce inflammation in the eye.

Thetreatmentalso gets a major leg up from proof of ability to go longer between injections.

Patients are understandably put off by an injection to the eyeball. Couple that with fears over COVID-19 exposure and sales of current Lucentis treatments seriously dipped in 2020 by 16%, about $1.6 billion.

Lucentisinjections wereneededmonthly for most patients.Competitor Eylea was needed monthly or bi-monthly, depending on the patient.The burden of treatment has proven to lead to under-treatment and therefore less than optimal outcomes for patients vision.

Faricimabspotential to extend time between treatments may benefit those patients who struggle to keep up with the regular physician visits and eye injections needed to preserve their vision,said Jeffrey Heier, M.D., Director of Retinal Research at Ophthalmic Consultants of Boston in Boston, Mass.

Genentechs clinical trial design was the proofin the pudding forthis new drug. The four studies consistently showedfaricimabto bejust aseffectiveas competitor Eylea even when administered at longer intervals. Half of the patients were able to be treated effectively once every four months. About75% were eligible for treatment every three monthsor longer.Both are a major improvement to patient convenience compared to monthly or even bi-monthly injections.

These positive results show the potential forfaricimabas the first new type of medicine in 15 years for people with neovascular age-related macular degeneration and in close to a decade in diabetic macular edema, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. This is an exciting time for our ophthalmology clinical development program, with multiple Phase III successes for two medicines from our late-stage pipeline. We hope to bring these potential treatments to people living with vision-threatening retinal conditions as soon as possible.

Genentech has not yet announced when they will seek FDA approval forfaricimabbut experts anticipate an aggressive timeline.

Most Read Today

Follow this link:
Genentech Could Regain the Blindness-Related Disease Market with New Treatment - BioSpace

Read More...

Prevent Blindness to Hold Sixteenth Annual "Eyes on Capitol Hill" Advocacy Event – Yahoo Finance

February 14th, 2021 7:23 pm

TipRanks

We are indeed living in interesting times and in many ways, thats a good thing. Take the automotive industry, for example. Technology is changing a rapid pace, and when it settles, it will dramatically change the way we drive. In 2030, our concept of car will likely be unrecognizable to drivers from 1980. The biggest changes are coming from power systems and artificial intelligence. AI will bring autonomous tech to our cars, making self-driving vehicles a reality. But the power systems changes will hit us first. In fact, electric-drive vehicles are already on our roads, and electric vehicle (EV) companies are proliferating rapidly. For the moment, there are several roads to potential success in the EV market. Companies are working to position themselves as leaders in battery tech, or electric power trains, or to maximize their range and performance per charge. Its a fact-paced industry environment, offering both opportunity and excitement for investors. Smart investors will look for companies capable of meeting scaling demands, once they have settled on marketable models. Investment firm Morgan Stanley has been watching the EV industry, seeking out innovative new design and production companies that are positioning themselves for gains as the market matures. The firms automotive analyst, Adam Jonas, has selected two stocks that investors should seriously consider buying into, saying As we survey the EV/battery startup landscape, we are prioritizing highly differentiated technology and/or business models with a path to scale at a reasonable level of risk. Opening up the TipRanks database, weve pulled up the details on both of Jonas picks to see whether they could be a good fit for your portfolio. Fisker (FSR) First up, Fisker, is based in Southern California, the epicenter of so much of our ground-breaking tech industries. Fiskers focus is on solid-state battery tech, a growing alternative to the lithium-ion batteries that most EVs depend on. While more expensive that the older lithium-based systems, solid state batteries are safer and offer higher energy densities. Fisker has been busy patenting its moves into solid-state batteries, a sound strategy to lock in its advances in this field. For EVs, solid-state batteries offer faster charging times, longer range per charge, and potentially lower battery weight all important factors in vehicle performance. Every car company needs a flagship model, and Fisker has the Ocean an EV SUV with a mid-range price ($37,499) and a long-range power system (up to 300 miles). The vehicle features stylish design and room mounted solar panels to supplement the charging system, and is scheduled to enter serial production for the markets in 2022. The stylish design reflects the sensibilities of the companys founder, Henrik Fisker, known for his work on the BMW Z8 and the Aston Martin DB9. Fisker entered the public markets through a SPAC merger agreement last fall. Since completing the SPAC transaction on October 29, shares in FSR are up 112%. Morgan Stanleys Jonas is impressed by this company, describing the value proposition of Fisker as design, time to market, clean sheet user experience and management expertise, and saying that the 4Q22 launch schedule for the Ocean is likely to be met. Fisker is specifically targeting the personal owned/passenger car business as opposed to commercial oriented end markets, where emotive design and user experience matter more. Additionally, the company wants to create an all-digital experience from the website to the app to the HMI in the car and continued customer engagement through its flexible lease product, Jonas added. In line with his upbeat outlook on the company (and the car), Jonas rates Fisker an Overweight (i.e. Buy), and sets a $27 price target suggesting an upside of 42% for the coming year. (To watch Jonas track record, click here) Turning to the TipRanks data, weve found that Wall Streets analysts hold a range of views on Fisker. The stock has a Moderate Buy analyst consensus rating, based on 7 reviews, including 4 Buys, 2 Holds, and 1 Sell. Shares are currently priced at $18.99, and the $21.20 average price target implies a one-year upside of ~12%. (See FSR stock analysis on TipRanks) QuantumScape (QS) Where Fisker is working on solid-state batteries in the context of vehicle production, QuantumScape is setting itself up as a leader in EV battery technology and a potential supplier of the next generation of battery and power systems for the EV market. QuantumScape designs and builds solid-state lithium-metal batteries, the highest energy density battery system currently available. The key advantages of the technology are in safety, lifespan, and charging times. Solid-state batteries are non-flammable; they last longer than lithium-ion batteries, with less capacity loss at the anode interface; and their composition allows faster charging, of 15 minutes or less to reach 80% capacity. QuantumScape is betting that these advantages will outweigh the technologys current higher cost, and create a new standard in EV power systems. The companys strongest tie to the EV production field is its connection with Volkswagen. The German auto giant put $100 million into QuantumScape in 2018, and an additional $200 million in 2020. The two companies are using their partnership to prepare for mass-scale development and production of solid-state batteries. Like Fisker, QuantumScape went public through a SPAC agreement late last year. The agreement, which closed on November 27, put the QS ticker in the public markets where it promptly surged above $130 per share. While the stock has since slipped, it remains up 47% from its NYSE opening. For Morgan Stanleys Jonas, involvement in QS stock comes with high risk, but also high potential reward. In fact, the analyst calls it, "The Biotech of Battery Development." "We believe their solid state technology addresses a very big impediment in battery science (energy density) that, if successful, can create extremely high value to a wide range of customers in the auto industry and beyond. The risks of moving from a single layer cell to a production car are high, but we think these are balanced by the commercial potential and the role of Volkswagen to help underwrite the early manufacturing ramp," Jonas explained. Noting that QS is a stock for the long haul, Jonas rates the shares an Overweight (i.e. Buy), and his $70 price target indicates confidence in an upside of 28% for one-year time horizon. Granted, not everyone is as enthusiastic about QS as Morgan Stanly. QS's Hold consensus rating is based on an even split between Buy, Hold, and Sell reviews. The shares are priced at $54.64 and their recent appreciation has pushed them well above the $46.67 average price target. (See QS stock analysis on TipRanks) To find good ideas for EV stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read the original here:
Prevent Blindness to Hold Sixteenth Annual "Eyes on Capitol Hill" Advocacy Event - Yahoo Finance

Read More...

No Valentines for Thousands of Couples That Remain Apart Due to COVID-19 – SchengenVisaInfo.com – SchengenVisaInfo.com

February 14th, 2021 7:23 pm

The legend says that in the 3rd century Rome lived a priest named Valentine, who married Roman soldiers with the women they were in love with, despite a law that prevented them from getting married.

Valentine, who later on was jailed for breaking the law, fell in love with his jailors blind daughter, whom he cured of blindness. Before he was executed, he wrote her a love message signed from your Valentine.

2020 may have needed a Valentine more than ever, to enable thousands and thousands of couples who were left apart for months, amid the Coronavirus outbreak, and the measures that were imposed in a bid of the governments to halt the spread of the infection, to reunite.

With entry bans in place, borders closed all over the world, embassies refusing to issue visas, and the absence of flights, thousands of lovers have had to spend the summer apart, thanksgiving, Christmas, the New Years Eve, and now even Saint Valentines day, the day of lovers.

Many of these people have once again taken the issue to Twitter, to protest the entry bans on the days that they were supposed to be with their significant other more than on any other day.

I woke up to a photo of my partner with a rose this is the most romantic its going to get today, wrote a Twitter user from Germany that goes by the handler @lealovinglifea1.

Many couples & families have been separated for almost a year now, and there is still no end in sight. How much longer do we have to suffer? another Twitter user wrote.

A tweet of the European Union Council asking Twitter users how many European languages can they say I love you in, and sharing a romantic soundtrack has upset many.

In 5 languages, but I cant say it to the one I love, Twitter user Alessandra Simoni answered among others.

Whereas, another Twitter user named Rita wrote that they [couples] dont need romantic soundtracks but need the EU to help them to reunite us with their non-EU partners no matter what language they speak.

Many of these couples now count over a year of being apart from each other, with no other option available for them that to hope this will soon end.

Spaniard Javier, on the story of whom SchengenVisaInfo.com previously reported, on Valentines day this year marked 416 days apart from his fianc Nazym, who is a Kazakh citizen. Desperate to find a solution, he has even proposed a hunger strike to push the government to undertake any measure in order to help their situation.

The rest is here:
No Valentines for Thousands of Couples That Remain Apart Due to COVID-19 - SchengenVisaInfo.com - SchengenVisaInfo.com

Read More...

Wearing Face Masks Could Make It More Challenging for You to Identify People; What’s The Catch? – Science Times

February 14th, 2021 7:23 pm

Many of us are used to seeing face masks but many still find it hard to recognize faces with the said covering on the face.

(Photo : Reuters Connect/Juan Medina)A man smokes a cigarette with his eyes covered by a face mask as he takes part in a protest against the use of protective masks during the coronavirus disease (COVID-19) pandemic, in Madrid, Spain

Unfortunately, while safety measures help deter and control coronavirus's spread, some individuals face a whole new covering problem: a touch of face blindness.

In a recentpreprint studyreported on the PsyArXiv Preprints server, researchers noticed that, relative to unmasked individuals, people were less likely to recognize masked images.

Although the study has not yet been peer-reviewed, further research is required. It revealed that participants find it challenging to identify masked faces that they might have suffered from face blindness.

However, something to bear in mind: only because you might be unable to recognize masked figures right now, that does not imply that you have face blindness, but it does go a small distance to explaining what dealing with the condition feels like. Here's what, in general, you ought to hear about face blindness.

Face blindness, also known as prosopagnosia, is a neurological condition that, according to theNational Institute of Neurological Disorders and Stroke(NINDS), relates to the failure to recognize images. There are various levels of face blindness. Some people will find it challenging to identify the face of the person. Others cannot differentiate between unfamiliar faces, and some will not discern faces from separate items in certain extreme situations.

Brad Duchaine, PhD, Dartmouth University professor of psychological and brain sciences,tells Healththat approximately one in 50 persons who suffer from facial blindness have a significant effect on their everyday lives.

Doctors think that face blindness is induced by brain defects or disability, especially the correct fusiform gyrus, or a certain fold in the brain that, according to the NINDS, helps with facial vision and memory. Some persons experience a lifespan of facial blindness. Others acquire it unexpectedly following brain injuries, such as stroke, head damage, or certain neurodegenerative disorders. Face blindness is not induced by visual deficiency, disabilities of literacy, or lack of memory.

ALSO READ:7 Tips to Avoid Fogging Your Eyeglasses While Wearing Face Masks

It is also interesting that while face blindness is not a typical autism spectrum disorder occurrence, it tends to be more frequent among children who have it, according to the NINDS, likely due to disrupted social progress. Yet in addition, face blindness can be challenging to live with individually and professionally. In rare situations, in photographs or mirrors, persons with facial blindness often struggle to recognize near relatives and even their own faces, Duchaine notes. They have difficulty following films and TV programs, as well.

While face covers can render facial identification challenging for anybody, and although masks do not cause true face blindness, as you would expect, they are not usually as big a concern for people with face blindness.

Duchaine said face masks make it more difficult to recognize others for people with face blindness. However, because many people with face blindness may not rely on the face as strongly, face masks might have less influence on them than individuals with regular face identification.

In reality, Duchaine recently went through responses from prosopagnosia patients who visited his research platform Faceblind.org (the research team involves doctors from Harvard University and London University) and he came across a message from a woman who said she "loves COVID-19 masks."

It's because they don't inhibit her ability to identify faces. Rather they impair her ability to recognize objects." Only something to think about the next time you do a double-take on a pal sporting a mask.

However, a shocking positive lining to masks might have been uncovered through recent findings from the U.S. We may be rendered more desirable by them.

Collaborativeresearchbetween the University of Pennsylvania and Temple University College of Health asked participants to rate the attractiveness of a cross-section of people with and without masks. When wearing a surgical-style mask, they observed that 70 percent of allegedly "average-looking" individuals were more desirable.

According toCBC.ca, research co-author and clinical psychologist David Sarwer said that either prominent characteristics or asymmetrical features of the lower face are camouflaged by the mask.

He explained that we see certain people as more attractive in reality since less attractive features are now concealed by the face's covering.

Sarwer suggests that another explanation is that the pupils, which are left visible, are essential indicators of facial beauty.

It's something we're trained from a very early age. Sarwer explained that we're taught to look them right in the eyes while we're talking to others as adults. Because we're definitely getting some of the socialization, as well as some ingrained biology that drives us to be drawn to the eyes of strangers.

ALSO READ:Which Offers the Best Protection? 8 Face Masks Ranked Based On Effectiveness

Check out more news and information onMedicine and Healthon Science Times.

See the original post here:
Wearing Face Masks Could Make It More Challenging for You to Identify People; What's The Catch? - Science Times

Read More...

Pastor’s Corner Articles of Faith – Mercy on the Blind – 2021-02-12 – Sierra Sun Times

February 14th, 2021 7:23 pm

February 12, 2021 - In the final few verses of the Gospel of Matthew Chapter 20, we read of Jesus encounter with two blind men. The duo desired to be healed of their blindness and had joined the great crowd that formed around Jesus. The Lord passes by and the two cry out, Lord, have mercy on us, Son of David! What happens next? In verse 31 we read, The crowd rebuked them, telling them to be silent, but they cried out all the more, Lord, have mercy on us, Son of David!

Jesus does heal their blindness, but let us look at this verse above. Do we understand what is going on here? In the crowd were the literal followers of Christ. The disciples were in the group along with those interested in just seeing what the big deal was. There were people there who would be followers of Christ after the resurrection. There would be others that would join the mob that wanted Christ crucified. All started rebuking the blind men from crying out to the Lord for mercy. As Christians, we can understand people who are not Christians doing this but again, followers of Christ were doing the rebuking as well.

The disciples, time after time, failed to get what Christ was saying. Here in this short passage, we see two blind men getting it. They call Christ the son of David, a term reserved for the Messiah. Those who could see Christ in the flesh did not understand. The two blind men knew more about Christ than his disciples. They did what we do, go to Christ to receive mercy and we are given it. Rest upon that Christian. You are forgiven.

Wynter is an Elder at Mariposa Reformed Baptist Church. Find out more at MariposaChurch.org or email him at wynter@mariposachurch.org. Visit Mariposa Reformed Baptist Church on Facebook.

Pastors Corner isa column from Pastor Wynter Sturtevant III of the Mariposa Reformed Baptist Church.

TheChurch has moved locations, services are now held at the Bootjack Stompers Hall (located at 4662 Morman Bar Crossing) across from the Mariposa County Fairgrounds.

Time of service is at 10:00 A.M. on Sunday.

I am happy to announce that MRBC has its own sermon podcast. Please check it out by clicking on the link below or searching MRBC Sermons on iTunes. New sermons will be posted every Wednesday.

https://mariposachurch.transistor.fm/episodes

Note: Area churches interested in submitting Articles of Faith are welcome to contact us.

Please email the Sierra Sun Times at sst@goldrushcam.comfor more information.

More:
Pastor's Corner Articles of Faith - Mercy on the Blind - 2021-02-12 - Sierra Sun Times

Read More...

Video: 6 Blind People, Including a Lebanese, Were Given A Camera And Told To Take Pictures – The961

February 14th, 2021 7:23 pm

In an inspiring documentary called Not Everything Is Black, six blind people from different cities around the world were encouraged to carry a camera and take photos of anything they wanted.

The documentary, which was initially released in 2019 and recently premiered on YouTube, aimed to grasp an understanding of how blind people perceive reality.

In Lebanon, young and adventurous Ramy Jarjoura put the camera up to his face to capture a picture of a bird in a cage as though from his own eyes.

Birds are trapped in a cage in need of freedom, and like birds, a blind person needs to escape the cage inside themselves in order to fly amongst others, he said.

He also expressed that he could relate to birds pain because of the accident that caused his blindness.

You see, Ramy began to go blind at the age of 10 after he was accidentally shot in the head by a bird hunter in the woods nearby his house.

In 2010, after many surgeries to try to restore his sight, he became completely blind. But to Ramy, it was a blessing in disguise.

I became blind in the sense most people understand blindness. But from my perspective, 2010 was when I began to see, he said.

His acceptance of the pain of his situation transformed into the strength that keeps him going.

When asked if he would ever like to see again, he tells people that he forgets that he cant see because of all the blessings he experiences from blindness.

Follow Ramy and others on their inspiring journey to capture photos by using their senses to visualize the world around them and also get inside their heads.

Watch the full documentary here:

See original here:
Video: 6 Blind People, Including a Lebanese, Were Given A Camera And Told To Take Pictures - The961

Read More...

Prem in FIFTH kit clash this season as up to 100,000 colour blind viewers cant tell Sheff Utd and Chelsea a – The Sun

February 14th, 2021 7:23 pm

UP to 100,000 colour blind fans were left furious on Sunday after Chelsea wore their light blue away kit at Sheffield United, making the match almost impossible to watch.

For the fifth time this season, colour blind Premier League supporters were barely able to distinguish between the sides due to the bizarre choice of jersey.

3

Chelsea wore their light blue away kit to take on the Blades in their predominantly white strip in Sky Sports' live showdown.

But fans were left perplexed, believing the West Londoners' home strip - a much deeper shade of blue - would have been less of a clash.

Opting for the almost-white away jerseys made life tough for those who suffer from colour blindness.

The Colour Blind Awareness charity predicted around 100,000 viewers for the game - a 2-1 win for Chelsea - would have suffered from colour blindness.

Read our Chelsea live blog for the very latest news from the Bridge

And fans took to Twitter in their droves to complain.

One wrote: "I turned it on, saw 20 matching shirts and simply turned it off again.

"I wonder where I could inquire to get some refunds for streaming expenses, since they are actively making it impossible to watch what I pay for."

Another said: "Someone with a bigger brain has got to explain how this is easier to see than Chelsea playing in their home BLUE kit?"

BET OF THE DAY: GET THE BEST FOOTBALL PRICES ON THE MARKET WITH OUR EXPERT ADVICE

3

A third sarcastically added: "Well done Chelsea. You really needed your almost white away kit for this fixture.

"The traditional blue would obviously have clashed with the mostly white shirts of Sheffield United."

Another viewer even called it 'blatant discrimination', tweeting: "It's been happening all season.

"So many kit clashes and absolutely nothing gets done about it, it's utterly shameful.

"People think colour blindness is a trivial issue. It's not.

"These kit clashes are ENTIRELY AVOIDABLE, that's the worst part of it. Blatant Discrimination!!'

It is the fifth time alone a Premier League clash has thrown up a colour-blindness issue, with Liverpool and Manchester United both featuring twice.

The game between the two rivals at Anfield last month was the most-watched Premier League game in history amongst Brits.

But of the five million who tuned in, a predicted 300,000 of those struggled to distinguish between the two sides.

3

Liverpool wore their red home strip, while Man Utd wore their 'earth green' alternate colours.

Reds and greens - particularly in similar shades - are almost impossible to distinguish between for those suffering from colour blindness.

That meant the red of Liverpool's socks merged with the green of the grass, while the deep shade of green in United's strip also clashed with that of the grass and the home side's red.

The Premier League has developed a 'colour blind friendly flag to help clubs pick the colours best-suited to all viewers.

However, the final say lies with the club.

And Colour Blindness Awareness spokesperson Kathryn Albany-Ward lashed out at the Premier League for their failure to act.

Albany-Ward said: "They know about this issue. They know it's disability discrimination and they are not doing enough about it."

Southampton vs Man Utd, Sheff Utd vs Southampton and Liverpool vs Crystal Palace have also been criticised for their lack of empathy to those suffering from colour blindness.

Around one in 12 men suffer from colour blindness, with the disability affecting roughly one in 200 women.

Here is the original post:
Prem in FIFTH kit clash this season as up to 100,000 colour blind viewers cant tell Sheff Utd and Chelsea a - The Sun

Read More...

Johnson & Johnson Vision Celebrates 20 Years of Helping Cataract Patients with the See More Campaign and Global Patient Story Search – PRNewswire

February 14th, 2021 7:23 pm

SANTA ANA, Calif., Feb. 9, 2021 /PRNewswire/ -- Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, today announces a month-long celebration of the 20th Anniversary of the TECNIS platform, the proprietary combination of materials and design on which Johnson & Johnson Vision IOLs (intraocular lenses) are built. Twenty years ago, a team of researchers and innovators created TECNIS, setting in motion two decades of breakthroughs, including the world's first aspherical lens and extended depth of focus lens. Today, notonly does TECNIS offer a distinct quality of vision1 that allows patients to "See More," it is also the broadest portfolio of IOLs worldwide, providing surgeons with a variety of solutions to treat different visual conditions.

"The innovation of the TECNIS platform was a revolutionary advancement in IOL design and composition that changed cataract surgery forever by introducing the concept of quality of vision," said Dr. Eric Donnenfeld, MD, Clinical Professor of Ophthalmology, New York University."*** "The TECNIS IOL was the first to employ negative spherical aberration and cancel the positive spherical aberration of the cornea achieving improved visual acuity, contrast sensitivity and reducing chromatic aberration. On behalf of my patients and my practice, congratulations to Johnson & Johnson Vision and TECNIS on 20 years of improving patient outcomes in cataract surgery."

"Many ophthalmologists can help restore their patients to 20/20 vision during their cataract procedureby addressing their patient's vision needs with a presbyopia-correcting IOL, a Toric IOL, or some combination of both. But quality vision is aboutso much more than the ability to see 20/20," said Rajesh K. Rajpal****, MD, Chief Medical Officer and Global Head of Clinical and Medical Affairs at Johnson & Johnson Vision. "It's about delivering clarity and contrast regardless of lighting or contrast conditions and sustaining that visual performance for the life of the lens. This month, we're celebrating TECNIS, because of the breakthrough 20 years ago, but also the breakthroughs it continues to enable today."

In celebration of 20 years, Johnson & Johnson Vision is launching the "See More" campaign to educate patients and physicians on what is possible with cataract surgery and how the TECNIS portfolio unlocks greater potential for patients. Additionally, Johnson & Johnson Vision is donating $20,000 to the Himalayan Cataract Project (HCP)|Cure Blindness in honor of the organization's dedication to spread cataract awareness. HCP | Cure Blindness is an independent, nonprofit organization that works to eradicate preventable blindness in countries across the globe and has screened and treated more than 11.5 million people and performed more than 940,000 surgeries in 20 countries.

Johnson & Johnson Vision will continue to roll out the campaign throughout 2021 by launching a global story search. Stories inside the U.S. about how cataract surgery has enabled patients to "See More" via video, photo or text will be collected at https://www.jjvision.com/tecnis-see-more; stories outside of the U.S. will be collected in accordance with the local and regional data privacy regulations. These "See More" patient stories will represent the true reach of the TECNIS platform.

"For two decades, we've dedicated ourselves to creating breakthroughs in cataract treatment and delivering the best optics available in terms of quality of vision. We believe the quality of the lens is only as good as the platform it is built on -- that's why TECNIS is both our legacy and our future. With the global expansion of our new TECNIS IOL lenses in 2021, we will be expanding access to the broadest IOL portfolio available on the market," said Nikki Sidi*****, Vice President, Global Strategic Marketing, Surgical Vision at Johnson & Johnson Vision. "We are excited to celebrate TECNIS 20th anniversary this yearand continue to offer more lenses to more patients than ever before."

In 2021, Johnson & Johnson Vision will continue to roll out new TECNIS IOLs across the globe including TECNIS Synergy IOL, TECNIS SymfonyIOL, and TECNIS Eyhance IOL, all available at launch with astigmatism correcting options under the next-generation Toric II platform.

Patients who want to learn more about the TECNISportfoliocan visit https://www.beyondcataracts.com/

About CataractsMore than 90% of people develop cataractsthe clouding and yellowing of the lens in the eyeby the age of 65.2 While part of the normal aging of the eye, left untreated, cataracts cause vision to deteriorate over time. In fact, cataracts are the leading cause of preventable blindness worldwide, impacting more than 100 million eyes.3 Cataract surgery is one of the most common outpatient procedures performed today and has a success rate of approximately 98%.4 Today, cataract treatments can also offer patients vision correction, reducing or eliminating the need for glasses, in addition to removing the cataract.5,6

About TECNISThe TECNIS platform offers the broadest portfolio of IOLs to serve patients with a variety of vision conditions and lifestyles; and equip them with the solutions they need to see efficiently, clearly and comfortably. The TECNIS Family of IOLs includes monofocals, multifocals, extended depth of focus (EDOF), and IOLs for those with or without astigmatism. The industry leading platform, which offers a variety of options for different visual conditions and lifestyles, delivers a unique combination of material, manufacturing, and design to deliver exceptional visual outcomes across all distances.

Important Safety InformationWhile complications are rare, there are risks to routine cataract surgery. This is irrelevant to the lens you choose. The problems could be minor, temporary, or affect your vision permanently. These may include worsening of your vision, bleeding, or infection. Pre-existing diseases or conditions (e.g., diabetes, heart disease, and previous eye trauma) may place you at higher risk of experiencing complications and/or more difficult recovery after routine cataract surgery. With some lenses, you may experience some loss in the sharpness of your vision, even with glasses. A small number of patients may want to have their IOL removed. This can be due to lens-related optical/visual symptoms. You should discuss all risks and benefits with your eye doctor before surgery.

About Johnson & Johnson Vision*At Johnson & Johnson Vision*, part of Johnson & Johnson Medical Devices Companies**, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us atjjvision.com, follow @JNJVision on Twitter,Johnson & Johnson Vision on LinkedIn, and@JNJVision on Facebook.

About Johnson & JohnsonMedical Devices Companies**At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people's healthcare experiences. In surgery, orthopaedics, vision, and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.

*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson's Medical Devices segment.

***Dr. Eric Donnenfeld is a paid consultant of Johnson & Johnson Vision, Inc.

****Dr. Rajesh K. Rajpal is an employee of Johnson & Johnson Surgical Vision, Inc., serving as Head of Clinical and Medical Affairs across both the Surgical Vision and Vision Care organizations.

*****Nikki Sidi is an employee of Johnson & Johnson Surgical Vision, Inc., serving as Vice President of Global Strategic Marketing across Surgical Vision at Johnson & Johnson Vision.

Johnson & Johnson Vision, 2021. All rights reserved.

1Data on File. Johnson & Johnson Surgical Vision, Inc. 20152Kellogg Eye Center. Cataract.https://www.umkelloggeye.org/conditions-treatments/cataract3World Health Organization. Blindness and Impairment.https://www.who.int/en/news-room/fact-sheets/detail/blindness-and-visual-impairment4Vision Health Initiative, Common Eye Disorders. Centers for Disease Control and Prevention.https://www.cdc.gov/visionhealth/basics/ced/index.html5All About Vision. Will I Need Glasses After Cataract Surgery?https://www.allaboutvision.com/conditions/faq-cataract-glasses-after-surgery.htm6Khandelwal SS, et. al. Effectiveness of multifocal and monofocal intraocular lenses for cataract surgery and lens replacement: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):863-875. doi: 10.1007/s00417-018-04218-6

SOURCE Johnson & Johnson Vision

https://www.jjvision.com

See more here:
Johnson & Johnson Vision Celebrates 20 Years of Helping Cataract Patients with the See More Campaign and Global Patient Story Search - PRNewswire

Read More...

No Color-Blind Road to Socialism in the U.S. – LA Progressive

February 14th, 2021 7:23 pm

The Democratic Party is not anti-racist because of its diversity; it is in fact becoming a more effective agent of a racist and imperialist state.

The year was 2011 and Occupy Wall Street protesters were gathering, and sleeping, at Zuccotti Park every single day to bring attention to the perils wrought on the 99 percent by the one percent. I was interning for a labor union at the time, and regularly visiting the Occupy Wall Street encampment to participate in its marches and rallies. The internship was coupled with labor studies courses that I attended with a mixture of union workers and students interested in the labor movement. A committed Occupy Wall Street organizer made an announcement in one of my courses that activists were planning a demonstration at Broadway Junction train station as part of a series of actions targeting the citys public transit riders. The organizer claimed that these actions had successfully brought thousands of people into the movement.

Broadway Junction is located in East New York, a majority Black neighborhood in Brooklyn. Occupy Wall Street protesters organizing at Zuccotti Park were overwhelmingly white and Occupy Wall Street organizers often treated racism as a peripheral problem that could be resolved through caucuses. I asked what kind of relationship Occupy organizers had developed with the Black community they hoped would join their rally. The answer was none. The demonstration ended up being a resounding failure, drawing just a fraction of the number of people that had turned out in more capital and student-intensive (white) areas of the city.

This experience provided a profound lesson in the failures of the politics of color-blindness. The Obama administration eventually deployed the FBI and DHS to assist local police in crushing Occupy Wall Street. Occupy Wall Street activists rendered politically homeless made up a large portion of the forces behind Bernie Sanders presidential campaign of 2016 and the push to elect Alexandria Ocasio Cortez, among others, to Congress two years later. These campaigns galvanized millions of young people and workers to vote on a platform of Medicare for All, a Green New Deal, student debt cancellation, and other universal policies.

That was the good. The bad was that racism and white supremacy remained a peripheral or non-existent issue in a struggle to elect progressive-sounding Democrats to implement a welfare state that the United States has never fully possessed in its two centuries-plus of existence. Just as Occupy Wall Street demanded nothing directly from the Obama administration, so too did newfound progressive Democratic Party activists largely avoid any kind of synthesis of eight years of Obama-rule. This allowed the capitalists in control of the party to wage an ideological war on mythical Bernie Bros and exploit color-blindness to their advantage. The masses of people supporting Sanders were all racist, we were told by the corporate media, because they did not specifically address issues particular to Black people.

The Democratic Party establishment began the work of normalizing endless war, austerity, and state sanctioned white supremacy.

Bernie Sanders did not help himself in this regard. While his policy agenda of Medicare for All and other universal policies would disproportionately benefit Black Americans, his unwillingness to publicly support reparations (despite no real commitment among the establishment of what form it would take) and his reluctance to focus campaign resources in heavily Black areas of the country opened a lane for his foes in the Democratic Party establishment to take the lead on the age-old debate of race versus class. Obama was summoned to whip the Democratic Party into shape , and the Black misleadership class coalesced around an anybody but Bernie political agenda. The elevation of Biden to the presidency, a barely functional modern-day corporate Dixiecrat, was the result of two consecutive primaries where Sanders stood silent as establishment Democrats took every measure possible to prevent his nomination.

It has been more than four years since Barack Obama was president of the United States yet his legacy continues to haunt the Left in ways that have gone unrecognized to the naked eye. Obama neutralized the left and consolidated the farce that the Democratic Party was an anti-racist institution because it was a diverse institution. At the same time, many in the Democratic Party, including large numbers of Black Americans, believed that white supremacy had been handed a significant defeat with the election of Barack Obama. This predictably angered many white Americans committed to the racist roots of American democracy. With the wages of whiteness diminishing, it was quite easy for Donald Trump to take hold over the White Mans GOP with a more enthusiastic brand of racist red meat posing as working class politics.

These developments were given birth on a bed of lies. The Democratic Party was not anti-racist because of its diversity; it was in fact becoming a more effective agent of a racist and imperialist state. Obama and his political minions helped fan the flames of heightening white anxiety by focusing all of their attention on the neutralization of the Left. And this didnt begin with the direct suppression of the Occupy Wall Street and Black Lives Matter movements or the broad assault on the left vis--vis Russiagate. It began when Obama was elected and the Democratic Party establishment began the work of normalizing endless war, austerity, and state sanctioned white supremacy to the point of rendering any kind of ideological coherence around these machinations of imperialism too difficult for so-called progressive forces to muster.

The Democratic Party has thus played a key role in both stoking color-blind racism and its ideological counterpart on the far right. Democrat-led anti-Russian racism justified U.S. aggression toward Russia and directly led to Trumps New Cold War on China and the Yellow Peril racism required to wage it. The mass deportation of undocumented immigrants, the mass transfer of military weaponry to localized occupation forces in the Black community otherwise known as the police, and the militarization of the African continent through the expansion AFRICOM are just a few of Obamas policies that helped expand the scope of racist wars of aggression at home and abroad. Over the course of two presidential terms, the most left-leaning section of the United States, Black America, became increasingly conservative and captive to the Democratic Partys political vise grip.

It should come as no surprise, then, that the first anti-establishment steps taken out of the crisis of capitalism in the United States are color-blind in character. But this doesnt make color-blindness correct. The Democratic Party is not an anti-racist institution and does not hold on a monopoly on the struggle against white supremacy. White supremacy forms the core of why the United States never had a welfare state to begin with and why, even at its height, the labor movement in the United States could barely reach half of the country let alone take state power. Furthermore, to paraphrase Dr. Charisse Burden-Stellys commentary on Luqman Nation, Black Americans have literally existed as capital in the form of slaves for longer than they have participated in the wage labor force in the United States. Continued racial disparities in healthcare, housing, incarceration, employment, and across all indicators of class antagonism cannot be fully explained without acknowledgement of the fact that the U.S. power structure has always been, and will always be, rooted in white supremacist domination.

The ongoing struggle for peace and socialism in the United States will need to wrestle the narrative of white supremacy away from the corporate jaws of the Democratic Party, which is fully invested in the profits enjoyed from the neoliberal decay of the capitalist system. This doesnt mean avoiding the question of white supremacy in the quest for an American unity that has never existed in any mass way in the United States.

It means engaging in struggle with the people directly in a manner that raises the contradictions of U.S. imperialism into full visibility and generates a real public debate. There will be no color-blind road to socialism in the United States but it is a forgone conclusion that white supremacy is the biggest impediment to actually traveling on a socialist path in the correct direction.

Danny HaiphongBlack Agenda Report

Read the original:
No Color-Blind Road to Socialism in the U.S. - LA Progressive

Read More...

City of Hope Renames World-Class Research Center the Arthur Riggs Diabetes & Metabolism Research Institute – Business Wire

February 14th, 2021 7:23 pm

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope, a world-renowned independent cancer and diabetes research and treatment center, today announced it has renamed its preeminent diabetes research center the Arthur Riggs Diabetes & Metabolism Research Institute, in honor of its longtime director and research pioneer. Riggs scientific achievements include developing the technology that led to the first synthetic human insulin a breakthrough that enabled mass production of insulin for people with diabetes. That discovery, which jumpstarted what is now a $500 billion global biotech industry, was followed by numerous firsts in the field of biomedical science. Today, synthetic insulin is used regularly by hundreds of millions of people.

Riggs, the Samuel Rahbar Chair in Diabetes & Drug Discovery, also developed recombinant DNA technology capable of producing humanized monoclonal antibodies that are the foundation of modern treatments for diabetes, cancer, autoimmune diseases, blindness and a host of other diseases. These therapies include trastuzumab (commercial name: Herceptin), rituximab (commercial name: Rituxan), pembrolizumab (commercial name: Keytruda) and many others that are some of the worlds most widely used cancer drugs.

Arthur Riggs is a true visionary and a scientific giant, said Robert Stone, president and CEO of City of Hope and the Helen and Morgan Chu Chief Executive Officer Distinguished Chair. Dr. Riggs has been essential to the institutes growth and accomplishments over five decades, as a researcher, discoverer, mentor and major donor. His contributions to biomedical research have transformed the lives of countless people living with serious diseases and his mark on City of Hope is an indelible one that will continue on in the institute that now bears his name.

At City of Hope, in addition to dedicating himself to scientific pursuits, Riggs has quietly contributed nearly all of the wealth from his discoveries to support leading-edge research toward the development of new treatments for the betterment of human health.

Over the past 30 years, Riggs has donated more than $310 million to City of Hope. His generosity culminated in a gift of $100 million in January 2021 that will help fund the continuation of research that has been his passion for more than half a century.

Until now, Riggs has insisted that his gifts remain anonymous so that any attention would not detract from his work. He elected to make his philanthropy public now in the hope of encouraging other donors to join City of Hopes fight against diabetes and cancer, especially at a time when new therapeutic discoveries are needed more than ever.

I came to City of Hope because the environment here offers exactly that hope for people with diabetes, cancer and many other serious diseases, Riggs said. I believe in the promise of our work at City of Hope so strongly that one day, probably sooner than most think, well create a world without diabetes. Yet, we will realize the full potential of this important work only through the generosity of many other donors who will choose to join us.

The Arthur Riggs Diabetes & Metabolism Research Institute is one of the worlds foremost scientific organizations dedicated to investigating the biology of diabetes and its treatment. It houses eight departments, including The Wanek Family Project for Type 1 Diabetes, and continues Riggs work under its newly appointed director, Debbie C. Thurmond, Ph.D., the Ruth B. & Robert K. Lanman Chair in Gene Regulation & Drug Discovery Research.

It has been a humbling honor to assume responsibility for this institute that Dr. Riggs so purposefully and painstakingly built, Thurmond said. Its entirely fitting that it should carry his name as we carry on the work he began for the benefit of people with diabetes. His philanthropy is an extension of the generosity of spirit he has shown to me and everyone else who has ever walked through these doors, and his impact will be with us for many years to come.

About City of HopeCity of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope, a wholly owned subsidiary, was launched in 2019 and is dedicated to serving employers and their health care partners by providing access to City of Hopes exceptional cancer expertise. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nations Best Hospitals in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

See the original post here:
City of Hope Renames World-Class Research Center the Arthur Riggs Diabetes & Metabolism Research Institute - Business Wire

Read More...

Pilots complain of laser lights targeting night flights – New Zealand Herald

February 14th, 2021 7:23 pm

Lasers can cause temporary blindness in pilots, aviation school CEO Ashok Poduval says. Photo / 123RF

By RNZ

Massey University's aviation school is warning people to stop shining lasers into planes at night because it could cause a pilot to crash.

School of Aviation chief executive Ashok Poduval said the lasers could cause temporary blindness.

"When they're flying at night you need to keep eyes adjusted to darkness and not have any bright lights around you, so when suddenly there's a flash of light your night vision is either completely reduced or completely removed."

Poduval said it was difficult to track down who was shining the beams up at the plane but police and the Civil Aviation Authority have been notified.

He said if anyone was caught, they could face charges for interfering with an aircraft.

Flight instructor Shannon Mickleburgh told Stuff pilots could get flash blindness where they could not see anything.

"It's quite disorientating when it does happen.

"The little laser on the ground ends up being quite bright by the time it makes it up to the aircraft.

"You've got a glass canopy so everything just reflects. It's extremely bright when it actually is on the canopy itself at night because you get accustomed to the darkness and all of a sudden you've got a bright light."

- RNZ, Stuff

See the original post here:
Pilots complain of laser lights targeting night flights - New Zealand Herald

Read More...

AMD Awareness Month sheds light on the leading cause of severe vision loss in older adults – Canada NewsWire

February 14th, 2021 7:23 pm

AMD affects the central vision and occurs when cells in the macula - a small area of the retina at the back of the eye - break down or deteriorate. While peripheral vision is not affected, one loses the sharp, straight-ahead vision that is necessary for driving, reading, recognizing faces, and looking at fine detail.

"Early on, there may not be any noticeable vision loss from age-related macular degeneration, especially if only one eye is affected, but your eye doctor can spot the most common signs before it gets worse," says Dr. Colin Mann, President of the Canadian Ophthalmological Society. "With treatment, we can delay the progression and prevent further vision loss in about 90 per cent of cases, so it's critical to have comprehensive eye exams at least once a year, particularly the older you are."

While age is the biggest factor, the causes of macular degeneration includegenetics and a mixture of other health and environmental factors. Particularly at risk are those with blue eyes, heart disease, high blood pressure and high cholesterol. Smokers, people who are overweight or have a family history of the disease may also be more likely to develop AMD.

Depending on which type of age-related macular degeneration someone has, vision loss either happens slowly or quickly. Nine out of 10 people with AMD have the atrophic or 'Dry' type, which usually progresses slowly over many years. On the other hand, 'Wet' AMD is less common but more serious, and can lead to vision loss quickly. Delays can result in poorer outcomes, so treating Wet AMD is time-sensitive.

Symptoms of AMD

In advanced stages, the more common symptoms of macular degeneration may include:

Early AMD changes can be detected at home by checking your vision in each eye with the use of an Amsler grid.

Treatment While there's no treatment for Dry AMD yet, a high-dose vitamin regimen hasbeen shown to reduce the rate of which people with advanced dry macular degeneration develop Wet AMD, and there are several promising drugs are undergoing clinical trials. Wet AMD is more rare, and is most commonly treated through injections directly into the eye with drugs that are very effective at causing the abnormal blood vessels to stop growing and leaking. The frequency of injections taper off after an initial period but lifelong treatment is required to prevent recurrence and vision loss.

Learn more about AMD, or one of the other four serious eye diseases, by visiting seethepossibilities.ca.

About Canadian Ophthalmological SocietyThe Canadian Ophthalmological Society (COS) is the national, recognized authority on eye and vision care in Canada. As eye physicians and surgeons, we are committed to assuring the provision of optimal medical and surgical eye care for all Canadians by promoting excellence in ophthalmology and by providing services to support our members in practice. Our membership includes over 900 ophthalmologists and 200 ophthalmology residents. We work collaboratively with government, other national and international specialty societies, our academic communities (ACUPO), our provincial partners and affiliates and other eye care professionals and patient groups to advocate for health policy in Canada in the area of eye and vision health. COS is an accredited, award-winning provider of Continuing Professional Development (CPD) through the Royal College of Physicians and Surgeons of Canada (RCPSC) and is an affiliate of the Canadian Medical Association (CMA). For more information, visit cos-sco.ca.

SOURCE Canadian Ophthalmological Society

For further information: Elizabeth Glassen, [emailprotected], 647.309.0141, BlueSky Communications

The rest is here:
AMD Awareness Month sheds light on the leading cause of severe vision loss in older adults - Canada NewsWire

Read More...

Page 229«..1020..228229230231..240250..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick